Accepted Manuscript

The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva

Dana M. Alessi Wolken, Vincent Idone, Sarah J. Hatsell, Paul B. Yu, Aris N. Economides

PII: S8756-3282(17)30210-7

DOI: doi: 10.1016/j.bone.2017.06.011

Reference: BON 11341

To appear in: Bone

Received date: 5 April 2017 Revised date: 2 June 2017 Accepted date: 15 June 2017

Please cite this article as: Dana M. Alessi Wolken, Vincent Idone, Sarah J. Hatsell, Paul B. Yu, Aris N. Economides, The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva, *Bone* (2017), doi: 10.1016/j.bone.2017.06.011

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.

Dana M. Alessi Wolken^a, Vincent Idone^a, Sarah J. Hatsell^a, Paul B. Yu^b, and Aris N. Economides^{a,c,*}.

Email address: aris@regeneron.com

Abstract

Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disorder that presents at birth with only minor patterning defects, but manifests its debilitating pathology early in life with episodic, yet progressive and cumulative, heterotopic ossification (HO) of ligaments, tendons, and a subset of major skeletal muscles. The resulting HO lesions are endochondral in nature, and appear to be linked to inflammatory stimuli arising in association with known injuries, or from inflammation linked to normal tissue repair. FOP is caused by gain-of-function mutations in ACVR1, which encodes a type I BMP receptor. Initial studies on the pathogenic mechanism of FOP-causing mutations in ACVR1 focused on the enhanced function of this receptor in response to certain BMP ligands, or independently of ligands, but did not directly address the fact that HO in FOP is episodic and inflammation-driven. Recently, we and others demonstrated that Activin A is an obligate factor for the initiation of HO in FOP, signaling aberrantly via mutant ACVR1 to transduce osteogenic signals and trigger heterotopic bone formation [1, 2]. Subsequently, we identified distinct tissue-resident mesenchymal progenitor populations residing in muscles and tendons that recognize Activin A as a pro-osteogenic signal (solely in the context of FOP-causing mutant ACVR1), and give rise to the cartilaginous anlagen that form heterotopic bone [3]. During the course of these studies, we also found that the activity of FOP-causing ACVR1 mutations does not by itself explain the triggered or inflammatory nature of HO in FOP, suggesting the importance of other inflammation-introduced factors or processes. This review presents a synthesis of these findings with a focus on the role of Activin A and inflammation in HO, and lays out perspectives for future research.

Keywords: Fibrodysplasia Ossificans Progressiva, heterotopic ossification, Activin A, ACVR1, anti-Activin antibody, progenitor cells

1. Introduction

^aRegeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591

^bDivision of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

^cRegeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown, NY 10591

^{*}Corresponding author at: Regeneron Pharmaceuticals, 777 Old Saw Mill River Road, Tarrytown, NY 10591

Download English Version:

https://daneshyari.com/en/article/8625070

Download Persian Version:

https://daneshyari.com/article/8625070

Daneshyari.com